Space & Defense entity
Every one of those 1 sits in a single category, aerospace. Of the tracked stories, 1 of 1 also mention Aemetis, the most common co-covered peer. Source depth averages 15 original sources per story, versus 2.9 across the same-window beat baseline.
Last mentioned: Mar 13, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, aerospace. Of the tracked stories, 1 of 1 also mention Aemetis, the most common co-covered peer. Source depth averages 15 original sources per story, versus 2.9 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 6.8. Mineralys Therapeutics appears in 1 tracked Space & Defense story from March 13, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Space & Defense stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mineralys Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Lorundrostat PDUFA Date
Target date for FDA decision on Mineralys' lead product candidate.
Nektar Phase 3 Launch
Nektar plans first patient randomization for its Atopic Dermatitis program.
Mineralys NDA Acceptance
FDA accepts Mineralys' NDA for lorundrostat for uncontrolled hypertension.
EHang Record Deliveries
EHang closes Q4 with 100 eVTOL units delivered and first GAAP profit.
HeartBeam FDA Clearance
HeartBeam secures 510(k) clearance for 12-lead ECG synthesis software.
EHang (EH) achieved its first quarterly GAAP profit on record eVTOL deliveries, signaling a commercial inflection point for Advanced Air Mobility. Simultaneously, Vuzix (VUZI) reported a 76% revenue surge in smart glasses and waveguide technology, underscoring robust demand for dual-use augmented reality systems.
Mineralys Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
